Disc Medicine prices $178M underwritten offering of 4.94M shares at $36.00

Disc Medicine, Inc.

Priced 4,944,000 shares at $36.00; gross proceeds ~$178M, net ~$172.3M.
Offering led by Frazier Life Sciences and Logos Capital with other institutional investors.
Net proceeds to fund clinical development, R&D, and working capital; cash runway extended into 2027.
Expected to close June 17, 2024; Leerink Partners acts as sole bookrunner.
Offered under effective shelf registration statement (Form S-3, No. 333-275652).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.